Personalized radiosensitized radioimmunotherapy for peritoneal dissemination
| Project/Area Number |
16K10375
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | National Institutes for Quantum and Radiological Science and Technology |
|---|
Principal Investigator |
Yoshii Yukie 国立研究開発法人量子科学技術研究開発機構, 放射線医学総合研究所 分子イメージング診断治療研究部, 主幹研究員(定常) (10397242)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 核医学 / PET / がん / 放射線 / 放射免疫療法 / 三次元培養 / 増感剤 / 個別化 / 放射線増感剤 / 個別化医療 |
|---|
| Outline of Final Research Achievements |
There is currently no effective treatment for peritoneal dissemination, and development of new treatment is needed. Radioimmunotherapy with antibodies labeled with therapeutic radionuclides is a promising method to treat peritoneal dissemination. We have previously reported that the radioimmunotherapy using the radionuclide 64Cu-labeled anti-EGFR antibody was effective for peritoneal dissemination of gastrointestinal cancers. However, further optimization is desired for use of this therapy. In this study, we developed a method to select sensitizers that are effective in radioimmunotherapy with 64Cu-labeled anti-EGFR antibody, with a 3D tumor cell culture screening. Also, we demonstrated that the drugs selected by the sensitizer screening are actually effective in vivo.
|
| Academic Significance and Societal Importance of the Research Achievements |
消化器がんは、本邦で罹患数が多く、死因上位を占める疾患である。また、消化器がんにおける腹腔内微小転移は現在有効な治療法がなく、新規治療法の開発が求められている。本研究では、3Dがん培養スクリーニングを用い、抗EGFR放射免疫療法においてがん特性に応じた効果的な増感剤を選択する方法を開発した。また、選択増感剤が、腹腔内微小転移に対し効果があることをマウスモデルを用い実証した。
|
Report
(4 results)
Research Products
(9 results)
-
-
-
[Presentation] Evaluation of a PET-guided surgery with 64Cu-labeled cetuximab to resect tumors deeply located in the mouse peritoneal cavity2018
Author(s)
Yukie Yoshii, Hideaki Tashima, Yuma Iwao, Hiroyuki Takuwa, Eiji Yoshida, Hidekatsu Wakizaka, Taiga Yamaya, Mitsuyoshi Yoshimoto, Hiroki Matsumoto, Ming-Rong Zhang, Aya Sugyo, Tsuji B Atsushi, Tatsuya Higashi
Organizer
12th World Congress of the World Federation of Nuclear Medicine and Biology
Related Report
Int'l Joint Research
-
[Presentation] PET-guided surgery system with 64Cu-PCTA-cetuximab for accurate resection of intraperitoneal tumors in a mice model2018
Author(s)
Yukie Yoshii, Hideaki Tashima, Yuma Iwao, Hiroyuki Takuwa, Eiji Yoshida, Hidekatsu Wakizaka, Taiga Yamaya, Mitsuyoshi Yoshimoto, Hiroki Matsumoto, Ming-Rong Zhang, Aya Sugyo, Atsushi B Tsuji, Tatsuya Higashi
Organizer
第13回日本分子イメージング学会
Related Report
-
[Presentation] Efficacy of combination use of intraperitoneal radioimmunotherapy and PET-guided surgery with 64Cu-labeled-cetuximab in a mice model of colon cancer peritoneal dissemination2018
Author(s)
Yukie Yoshii, Mitsuyoshi Yoshimoto, Hiroki Matsumoto, Hideaki Tashima, Yuma Iwao, Hiroyuki Takuwa, Eiji Yoshida, Hidekatsu Wakizaka, Taiga Yamaya, Ming-Rong Zhang, Aya Sugyo, Sayaka Hanadate, Atsushi B. Tsuji, Tatsuya Higashi
Organizer
SNM Annual Meeting 2018
Related Report
Int'l Joint Research
-
[Presentation] Feasibility of a PET-guided surgery system with 64Cu-labeled-cetuximab in an orthotopic mouse model of pancreatic cancer2018
Author(s)
Kohei Sakurai, Yukie Yoshii, Hideaki Tashima, Yuma Iwao, Yoko Oe, Mineko Igarashi, Sayaka Hanadate, Eiji Yoshida, Hidekatsu Wakizaka, Taiga Yamaya, Mitsuyoshi Yoshimoto, Hiroki Matsumoto, Ming-Rong Zhang, Tsuji B Atsushi, Tatsuya Higashi
Organizer
SNM Annual Meeting 2018
Related Report
Int'l Joint Research
-
-
-
